Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Gross Margin (2019 - 2023)

Benitec Biopharma has reported Gross Margin over the past 5 years, most recently at 100.0% for Q2 2023.

  • Quarterly results put Gross Margin at 100.0% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 1471.43% (down 155819.0% YoY), and the annual figure for FY2023 was 100.0%, up 1233.0%.
  • Gross Margin reached 100.0% in Q2 2023 per BNTC's latest filing, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q4 2021 and bottomed at 1800.0% in Q4 2020.
  • Median Gross Margin over the past 5 years was 21.21% (2019), compared with a mean of 182.68%.
  • The largest annual shift saw Gross Margin plummeted -150260bps in 2020 before it skyrocketed 190000bps in 2021.
  • Over 5 years, Gross Margin stood at 297.4% in 2019, then tumbled by -505bps to 1800.0% in 2020, then surged by 106bps to 100.0% in 2021, then changed by 0bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • Business Quant data shows Gross Margin for BNTC at 100.0% in Q2 2023, 100.0% in Q1 2023, and 100.0% in Q4 2022.